Joseph A Trapani

List of Publications by Year
in descending order

147 papers	13,111 citations	22153 59 h-index	23533 111 g-index
152 all docs	152 docs citations	152 times ranked	13679 citing authors

#	Article	IF	Citations
1	Functional significance of the perforin/granzyme cell death pathway. Nature Reviews Immunology, 2002, 2, 735-747.	22.7	994
2	Perforin and granzymes: function, dysfunction and human pathology. Nature Reviews Immunology, 2015, 15, 388-400.	22.7	858
3	Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells. Journal of Experimental Medicine, 2000, 191, 661-668.	8.5	720
4	A fresh look at tumor immunosurveillance and immunotherapy. Nature Immunology, 2001, 2, 293-299.	14.5	650
5	Perforin-mediated target-cell death and immune homeostasis. Nature Reviews Immunology, 2006, 6, 940-952.	22.7	494
6	Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma. Journal of Experimental Medicine, 2000, 192, 755-760.	8.5	481
7	Granzymes: exogenous porteinases that induce target cell apoptosis. Trends in Immunology, 1995, 16, 202-206.	7.5	369
8	The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature, 2010, 468, 447-451.	27.8	364
9	Initiation of Apoptosis by Granzyme B Requires Direct Cleavage of Bid, but Not Direct Granzyme Bâ€“Mediated Caspase Activation. Journal of Experimental Medicine, 2000, 192, 1403-1414.	8.5	331
10	The Ced-3/Interleukin 1Î² Converting Enzyme-like Homolog Mch6 and the Lamin-cleaving Enzyme Mch2Î± Are Substrates for the Apoptotic Mediator CPP32. Journal of Biological Chemistry, 1996, 271, 27099-27106.	3.4	269
11	A Cytosolic Granzyme B Inhibitor Related to the Viral Apoptotic Regulator Cytokine Response Modifier A Is Present in Cytotoxic Lymphocytes. Journal of Biological Chemistry, 1996, 271, 27802-27809.	3.4	265
12	The MACPF/CDC family of pore-forming toxins. Cellular Microbiology, 2008, 10, 1765-1774.	2.1	250
13	Tumor immune evasion arises through loss of TNF sensitivity. Science Immunology, 2018, 3, .	11.9	244
14	Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene, 1997, 15, 453-457.	5.9	238
15	Granzyme B: pro-apoptotic, antiviral and antitumor functions. Current Opinion in Immunology, 2003, 15, 533-543.	5.5	218
16	Granzyme B (GraB) Autonomously Crosses the Cell Membrane and Perforin Initiates Apoptosis and GraB Nuclear Localization. Journal of Experimental Medicine, 1997, 185, 855-866.	8.5	216
17	Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack. Blood, 2013, 121, 2659-2668.	1.4	208
18	Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. Journal of Experimental Medicine, 2015, 212, 307-317.	8.5	188

#	Article	IF	Citations
19	The major human and mouse granzymes are structurally and functionally divergent. Journal of Cell Biology, 2006, 175, 619-630.	5.2	187
20	Cytosolic Delivery of Granzyme B by Bacterial Toxins: Evidence that Endosomal Disruption, in Addition to Transmembrane Pore Formation, Is an Important Function of Perforin. Molecular and Cellular Biology, 1999, 19, 8604-8615.	2.3	185
21	Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion. Cancer Research, 2020, 80, 4129-4144.	0.9	179
22	TRAIL+ NK Cells Control CD4+ T Cell Responses during Chronic Viral Infection to Limit Autoimmunity. Immunity, 2014, 41, 646-656.	14.3	158
23	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood, 2011, 117, 1605-1613.	1.4	152
24	Caspase Activation by Granzyme B Is Indirect, and Caspase Autoprocessing Requires the Release of Proapoptotic Mitochondrial Factors. Immunity, 2003, 18, 319-329.	14.3	147
25	Untimely TGFÎ² responses in COVID-19 limit antiviral functions of NK cells. Nature, 2021, 600, 295-301.	27.8	146
26	Calcium-dependent Plasma Membrane Binding and Cell Lysis by Perforin Are Mediated through Its C2 Domain. Journal of Biological Chemistry, 2005, 280, 8426-8434.	3.4	131
27	Apoptosis induced by the lymphocyte effector molecule perforin. Current Opinion in Immunology, 2007, 19, 339-347.	5.5	123
28	The Molecular Basis for Perforin Oligomerization and Transmembrane Pore Assembly. Immunity, 2009, 30, 684-695.	14.3	123
29	Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9809-9814.	7.1	114
30	Conformational Changes during Pore Formation by the Perforin-Related Protein Pleurotolysin. PLoS Biology, 2015, 13, e1002049.	5.6	114
31	Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nature Immunology, 2020, 21, 914-926.	14.5	114
32	Granzyme M Mediates a Novel Form of Perforin-dependent Cell Death. Journal of Biological Chemistry, 2004, 279, 22236-22242.	3.4	113
33	A Central Role for Bid in Granzyme B-induced Apoptosis. Journal of Biological Chemistry, 2005, 280, 4476-4482.	3.4	111
34	CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells. Cancer Immunology Research, 2015, 3, 483-494.	3.4	103
35	A clathrin/dynamin- and mannose-6-phosphate receptorâ€“independent pathway for granzyme Bâ€“induced cell death. Journal of Cell Biology, 2003, 160, 223-233.	5.2	99
36	Localization of Granzyme B in the Nucleus. Journal of Biological Chemistry, 1996, 271, 4127-4133.	3.4	97

#	Article	IF	Citations
37	Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nature Immunology, 2021, 22, 851-864.	14.5	97
38	Nuclear Transport of Granzyme B (Fragmentin-2). Journal of Biological Chemistry, 1996, 271, 30781-30789.	3.4	96
39	Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16. Oncogene, 2000, 19, 6033-6042.	5.9	95
40	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. Clinical Cancer Research, 2017, 23, 2478-2490.	7.0	95
41	A functional analysis of the putative polymorphisms A91V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis. Blood, 2005, 105, 4700-4706.	1.4	92
42	Cytotoxic T lymphocyteâ€“induced killing in the absence of granzymes A and B is unique and distinct from both apoptosis and perforin-dependent lysis. Journal of Cell Biology, 2006, 173, 133-144.	5.2	90
43	CTL granules: evolution of vesicles essential for combating virus infections. Trends in Immunology, 1999, 20, 351-356.	7.5	89
44	Real-time visualization of perforin nanopore assembly. Nature Nanotechnology, 2017, 12, 467-473.	31.5	88
45	Cutting Edge: Granzymes A and B Are Not Essential for Perforin-Mediated Tumor Rejection. Journal of Immunology, 2003, 171, 515-518.	0.8	86
46	Perforin activity and immune homeostasis: the common A91V polymorphism in perforin results in both presynaptic and postsynaptic defects in function. Blood, 2007, 110, 1184-1190.	1.4	82
47	Granzymes: a variety of serine protease specificities encoded by genetically distinct subfamilies. Journal of Leukocyte Biology, 1996, 60, 555-562.	3.3	79
48	Gene-Engineered T Cells as a Superior Adjuvant Therapy for Metastatic Cancer. Journal of Immunology, 2004, 173, 2143-2150.	0.8	77
49	Cationic Sites on Granzyme B Contribute to Cytotoxicity by Promoting Its Uptake into Target Cells. Molecular and Cellular Biology, 2005, 25, 7854-7867.	2.3	75
50	Rapid and Unidirectional Perforin Pore Delivery at the Cytotoxic Immune Synapse. Journal of Immunology, 2013, 191, 2328-2334.	0.8	72
51	Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death. Trends in Immunology, 2012, 33, 406-412.	6.8	71
52	Perforin-dependent nuclear entry of granzyme B precedes apoptosis, and is not a consequence of nuclear membrane dysfunction. Cell Death and Differentiation, 1998, 5, 488-496.	11.2	70
53	The dual adverse effects of TGF-Î² secretion on tumor progression. Cancer Cell, 2005, 8, 349-350.	16.8	70
54	The Functional Basis for Hemophagocytic Lymphohistiocytosis in a Patient with Co-inherited Missense Mutations in the Perforin (PFN1) Gene. Journal of Experimental Medicine, 2004, 200, 811-816.	8.5	67

#	Article	IF	Citations
55	Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3â^' Cellâ€"Mediated Modulation of CD103+ Dendritic Cells. Cancer Immunology Research, 2018, 6, 1069-1081.	3.4	67
56	Dual Mechanisms of Apoptosis Induction by Cytotoxic Lymphocytes. International Review of Cytology, 1998, 182, 111-192.	6.2	64
57	Processing of the Nedd2 precursor by ICEâ€like proteases and granzyme B. Genes To Cells, 1996, 1, 673-685.	1.2	63
58	Residual active granzyme B in cathepsin Câ€"null lymphocytes is sufficient for perforin-dependent target cell apoptosis. Journal of Cell Biology, 2007, 176, 425-433.	5.2	63
59	Protection from Endogenous Perforin: Glycans and the C Terminus Regulate Exocytic Trafficking in Cytotoxic Lymphocytes. Immunity, 2011, 34, 879-892.	14.3	63
60	IFI 16 gene encodes a nuclear protein whose expression is induced by interferons in human myeloid leukaemia cell lines. Journal of Cellular Biochemistry, 1995, 57, 39-51.	2.6	62
61	A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. Cancer Research, 2017, 77, 1296-1309.	0.9	61
62	Perforinopathy: A Spectrum of Human Immune Disease Caused by Defective Perforin Delivery or Function. Frontiers in Immunology, 2013, 4, 441.	4.8	58
63	Human perforin mutations and susceptibility to multiple primary cancers. OncoImmunology, 2013, 2, e24185.	4.6	57
64	Lipid order and charge protect killer T cells from accidental death. Nature Communications, 2019, 10, 5396.	12.8	56
65	Activation of cytotoxic cells in hyperplastic lymph nodes from HIV-infected patients. Aids, 1991, 5, 1071-1080.	2.2	54
66	Epigenetic control of mitochondrial cell death through PACS1-mediated regulation of BAX/BAK oligomerization. Cell Death and Differentiation, 2017, 24, 961-970.	11.2	52
67	ESCRT-mediated membrane repair protects tumor-derived cells against T cell attack. Science, 2022, 376, 377-382.	12.6	47
68	HIN-200: a novel family of IFN-inducible nuclear proteins expressed in leukocytes. Journal of Leukocyte Biology, 1996, 60, 310-316.	3.3	46
69	SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cells. Science Advances, 2021, 7, .	10.3	46
70	Addressing the mysteries of perforin function. Immunology and Cell Biology, 2006, 84, 66-71.	2.3	43
71	Heterozygosity for the common perforin mutation, p.A91V, impairs the cytotoxicity of primary natural killer cells from healthy individuals. Immunology and Cell Biology, 2015, 93, 575-580.	2.3	42
72	Killing by cytotoxic T cells and natural killer cells: Multiple granule serine proteases as initiators of DNA fragmentation. Immunology and Cell Biology, 1993, 71, 201-208.	2.3	41

#	Article	IF	Citations
73	Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. Haematologica, 2020, 105, e76-e79.	3.5	37
74	Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance. Nature Communications, 2021, 12, 4270.	12.8	37
75	Serglycin determines secretory granule repertoire and regulates natural killer cell and cytotoxic T lymphocyte cytotoxicity. FEBS Journal, 2016, 283, 947-961.	4.7	31
76	The Perforin Pore Facilitates the Delivery of Cationic Cargos. Journal of Biological Chemistry, 2014, 289, 9172-9181.	3.4	30
77	The closely linked genes encoding the myeloid nuclear differentiation antigen (MNDA) and IFI16 exhibit contrasting haemopoietic expression. Immunogenetics, 1995, 41, 40-43.	2.4	29
78	The use of chimeric human FcÎµ receptor I to redirect cytotoxic T lymphocytes to tumors. Journal of Leukocyte Biology, 1996, 60, 721-728.	3.3	28
79	Regulation of perforin activation and preâ€synaptic toxicity through Câ€terminal glycosylation. EMBO Reports, 2017, 18, 1775-1785.	4.5	27
80	Immune profiling of pediatric solid tumors. Journal of Clinical Investigation, 2020, 130, 3391-3402.	8.2	27
81	Structural Basis for Ca2+-mediated Interaction of the Perforin C2 Domain with Lipid Membranes. Journal of Biological Chemistry, 2015, 290, 25213-25226.	3.4	25
82	HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors. Cancer Research, 2017, 77, 2594-2606.	0.9	23
83	Enhancing chimeric antigen receptor Tâ€cell immunotherapy against cancer using a nanoemulsionâ€based vaccine targeting crossâ€presenting dendritic cells. Clinical and Translational Immunology, 2020, 9, e1157.	3.8	23
84	Measuring cell death mediated by cytotoxic lymphocytes or their granule effector molecules. Methods, 2008, 44, 241-249.	3.8	22
85	Diarylthiophenes as inhibitors of the pore-forming protein perforin. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 355-360.	2.2	22
86	Down-regulation of a pro-apoptotic pathway regulated by PCAF/ADA3 in early stage gastric cancer. Cell Death and Disease, 2018, 9, 442.	6.3	20
87	The granzyme B gene is highly polymorphic in wild mice but essentially invariant in common inbred laboratory strains. Tissue Antigens, 2007, 70, 198-204.	1.0	19
88	A Renaissance in Understanding the Multiple and Diverse Functions of Granzymes?. Immunity, 2008, 29, 665-667.	14.3	19
89	Recognition of the Major Histocompatibility Complex (MHC) Class Ib Molecule H2-Q10 by the Natural Killer Cell Receptor Ly49C. Journal of Biological Chemistry, 2016, 291, 18740-18752.	3.4	19
90	Missense mutations in the perforin (PRF1) gene as a cause of hereditary cancer predisposition. OncoImmunology, 2016, 5, e1179415.	4.6	18

#	Article	IF	Citations
91	PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia. Haematologica, 2021, 106, 3115-3124.	3.5	17
92	Distinct granzyme expression in human CD3- CD56+ large granular- and CD3- CD56+ small high density-lymphocytes displaying non-MHC-restricted cytolytic activity. Journal of Leukocyte Biology, 1995, 57, 88-93.	3.3	16
93	Defining the interaction of perforin with calcium and the phospholipid membrane. Biochemical Journal, 2013, 456, 323-335.	3.7	16
94	A Natural Genetic Variant of Granzyme B Confers Lethality to a Common Viral Infection. PLoS Pathogens, 2014, 10, e1004526.	4.7	16
95	Bi-Allelic Mutations in STXBP2 Reveal a Complementary Role for STXBP1 in Cytotoxic Lymphocyte Killing. Frontiers in Immunology, 2018, 9, 529.	4.8	16
96	IFN-Î³+ cytotoxic CD4+ T lymphocytes are involved in the pathogenesis of colitis induced by IL-23 and the food colorant Red 40. , 2022, 19, 777-790.		16
97	B cellâ€derived circulating granzyme B is a feature of acute infectious mononucleosis. Clinical and Translational Immunology, 2015, 4, e38.	3.8	15
98	CAR-T cells are serial killers. OncoImmunology, 2015, 4, e1053684.	4.6	14
99	Late-Onset Non-HLH Presentations of Growth Arrest, Inflammatory Arachnoiditis, and Severe Infectious Mononucleosis, in Siblings with Hypomorphic Defects in UNC13D. Frontiers in Immunology, 2017, 8, 944.	4.8	14
100	B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21. International Immunology, 2014, 26, 383-395.	4.0	13
101	A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer. Oncotarget, 2016, 7, 34582-34598.	1.8	13
102	Challenges of PD-L1 testing in non-small cell lung cancer and beyond. Journal of Thoracic Disease, 2020, 12, 4541-4548.	1.4	13
103	Natural killer cells kill extracellular Pseudomonas aeruginosa using contact-dependent release of granzymes B and H. PLoS Pathogens, 2022, 18, e1010325.	4.7	13
104	Imaging immunity in patients with cancer using positron emission tomography. Npj Precision Oncology, 2022, 6, 24.	5.4	13
105	Benzenesulphonamide inhibitors of the cytolytic protein perforin. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1050-1054.	2.2	12
106	Tumor-mediated apoptosis of cancer-specific T lymphocytesâ€"Reversing the â€œkiss of deathâ€?. Cancer Cell, 2002, 2, 169-171.	16.8	10
107	Infective, Neoplastic, and Homeostatic Sequelae of the Loss of Perforin Function in Humans. Advances in Experimental Medicine and Biology, 2007, 601, 235-242.	1.6	10
108	The pore conformation of lymphocyte perforin. Science Advances, 2022, 8, eabk3147.	10.3	10

#	Article	IF	Citations
109	A Method for Detecting Intracellular Perforin in Mouse Lymphocytes. Journal of Immunology, 2014, 193, 5744-5750.	0.8	9
110	Crossâ€talk between tumors at anatomically distinct sites. FEBS Journal, 2021, 288, 81-90.	4.7	9
111	Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma. Cancers, 2021, 13, 4704.	3.7	9
112	The complex issue of regulating perforin expression. Trends in Immunology, 2007, 28, 243-245.	6.8	8
113	Myeloma natural killer cells are exhausted and have impaired regulation of activation. Haematologica, 2021, 106, 2522-2526.	3.5	8
114	BET Inhibition Enhances TNF-Mediated Antitumor Immunity. Cancer Immunology Research, 2022, 10, 87-107.	3.4	8
115	Use of the 5â€² -flanking region of the mouse perforin gene to express human FcÎ³ receptor I in cytotoxic T lymphocytes. Journal of Leukocyte Biology, 1994, 55, 514-522.	3.3	7
116	Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects. Cancer Immunology, Immunotherapy, 1998, 47, 191-197.	4.2	7
117	Substituted arylsulphonamides as inhibitors of perforin-mediated lysis. European Journal of Medicinal Chemistry, 2017, 137, 139-155.	5.5	7
118	Distinguishing perforin-mediated lysis and granzyme-dependent apoptosis. Methods in Enzymology, 2019, 629, 291-306.	1.0	7
119	Inhibition of the Cytolytic Protein Perforin Prevents Rejection of Transplanted Bone Marrow Stem Cells in Vivo. Journal of Medicinal Chemistry, 2020, 63, 2229-2239.	6.4	7
120	Lipid specificity of the immune effector perforin. Faraday Discussions, 2021, 232, 236-255.	3.2	7
121	Targeting Lewis Y-Positive Multiple Myeloma and Acute Myeloid Leukemia with Gene-Modified T Cells Demonstrating Memory Phenotype. Blood, 2008, 112, 3900-3900.	1.4	7
122	Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation. , 2022, 10, e004095.		7
123	A Colorimetric Assay that Specifically Measures Granzyme B Proteolytic Activity: Hydrolysis of Boc-Ala-Ala-Asp-S-Bzl. Journal of Visualized Experiments, 2014, , e52419.	0.3	6
124	Perforin-dependent cytotoxicity: â€˜Kiss of deathâ€™ or prolonged embrace with darker elocation-idnseque11es?. OncoImmunology, 2015, 4, e1036215.	4.6	6
125	Prevalence and disease predisposition of p.A91V perforin in an aged population of European ancestry. Blood, 2020, 135, 582-584.	1.4	6
126	Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors. Biomedicines, 2021, 9, 1798.	3.2	6

#	Article	IF	Citations
127	Lymphocyte granule-mediated cell death. Seminars in Immunopathology, 1998, 19, 323-343.	4.0	5
128	Adaptive reprogramming of NK cells in X-linked lymphoproliferative syndrome. Blood, 2018, 131, 699-702.	1.4	5
129	Response: dexamethasone dose alters expression of NK activating receptors in vivo. Blood, 2011, 118, 6466-6468.	1.4	4
130	Analysis of Perforin Assembly by Quartz Crystal Microbalance Reveals a Role for Cholesterol and Calcium-independent Membrane Binding. Journal of Biological Chemistry, 2015, 290, 31101-31112.	3.4	4
131	Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib. OncoImmunology, 2015, 4, e1038011.	4.6	4
132	Antigenâ€specific<scp>CD</scp>4⁺<scp>CD</scp>25⁺T cells induced by locally expressed<scp>ICOS</scp>â€lg: the role of Foxp3, Perforin, Granzyme B and<scp>IL</scp>â€10 â€an experimental study. Transplant International, 2019, 32, 1203-1215.	1.6	4
133	Expression of human perforin in a mouse cytotoxic T lymphocyte cell line: evidence for perturbation of granule-mediated cytotoxicity. Journal of Leukocyte Biology, 1993, 54, 528-533.	3.3	3
134	Dissecting the apoptotic mechanisms of chemotherapeutic drugs and lymphocytes to design effective anticancer therapies. Drug Development Research, 2001, 52, 549-557.	2.9	3
135	A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in Mice. Biology of Blood and Marrow Transplantation, 2015, 21, 242-249.	2.0	3
136	Preclinical Activity and Pharmacokinetic/Pharmacodynamic Relationship for a Series of Novel Benzenesulfonamide Perforin Inhibitors. ACS Pharmacology and Translational Science, 2022, 5, 429-439.	4.9	3
137	Immune surveillance of lymphoma in humans?. Blood, 2005, 105, 4159-4160.	1.4	2
138	Recovery of natural killer cell cytotoxicity in a A91V perforinhomozygous patient following severe haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2020, 190, 458-461.	2.5	2
139	Differential cleavage of viral polypeptides by allotypic variants of granzyme B skews immunity to mouse cytomegalovirus. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2020, 1868, 140457.	2.3	2
140	Bigger, Stronger, Faster: Chimeric Antigen Receptor T Cells Are Olympic Killers. Blood, 2016, 128, 814-814.	1.4	2
141	Lymphocyte-Mediated Cytolysis Role of Granule Mediators. Blood Cell Biochemistry, 1991, , 143-162.	0.3	1
142	In vitro and in vivo antitumour activity of a chimeric anti-CD19 antibody. Cancer Immunology, Immunotherapy, 1995, 41, 53-60.	4.2	1
143	Granzymes. , 1998, , 1026-1030.		0
144	Cytotoxic Granules House Potent Proapoptotic Toxins Critical for Antiviral Responses and Immune Homeostasis. , 0, , 106-122.		0

#	Article	IF	Citations
145	Words of Advice: choosing the right lab for your postâ€doctoral fellowship. FEBS Journal, 2021, 288, 1734-1741.	4.7	0
146	Activated T Cells Express a Non-HLA-ABC Class I Gene that Is Inducible with Gamma-Interferon. , 1989, , 161-163.		0
147	Lymphocyte-Mediated Cytolysis: Dual Apoptotic Mechanisms with Overlapping Cytoplasmic and Nuclear Signalling Pathways. Results and Problems in Cell Differentiation, 1999, , 77-102.	0.7	0